User profiles for TAKAKO MIYAMAE

Takako Miyamae

Tokyo Women's Medical University
Verified email at twmu.ac.jp
Cited by 4690

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

S Yokota, T Imagawa, M Mori, T Miyamae, Y Aihara… - The Lancet, 2008 - thelancet.com
Background Systemic-onset juvenile idiopathic arthritis does not always respond to available
treatments, including antitumour necrosis factor agents. We investigated the efficacy and …

Therapeutic efficacy of humanized recombinant anti–interleukin‐6 receptor antibody in children with systemic‐onset juvenile idiopathic arthritis

S Yokota, T Miyamae, T Imagawa, N Iwata… - Arthritis & …, 2005 - Wiley Online Library
Objective To investigate the safety and efficacy of a recombinant human anti–interleukin‐6 (anti–IL‐6)
receptor monoclonal antibody (MRA) that indirectly inhibits the effects of IL‐6 in …

Follistatin-like protein-1 is a novel proinflammatory molecule

T Miyamae, AD Marinov, D Sowders… - The Journal of …, 2006 - journals.aai.org
While analyzing gene expression in collagen-induced arthritis, we discovered that a poorly
characterized gene, follistatin-like protein 1 (FSTL-1), is highly overexpressed in mouse paws …

Hypothetical pathophysiology of acute encephalopathy and encephalitis related to influenza virus infection and hypothermia therapy

S Yokota, T Imagawa, T Miyamae, SI Ito… - Pediatrics …, 2000 - Wiley Online Library
Background : To establish a treatment strategy for acute encephalopathy and encephalitis
associated with influenza virus infection, the pathophysiology of the disease was investigated …

Milk fat globule EGF factor 8 in the serum of human patients of systemic lupus erythematosus

H Yamaguchi, J Takagi, T Miyamae… - Journal of Leucocyte …, 2008 - academic.oup.com
Mouse milk fat globule epidermal growth factor 8 (MFG-E8), which is secreted by a subset of
activated macrophages, binds to apoptotic cells by recognizing phosphatidylserine and …

Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis

T Imagawa, S Yokota, M Mori, T Miyamae… - Modern …, 2012 - academic.oup.com
We evaluated the safety and efficacy of tocilizumab in polyarticular-course juvenile
idiopathic arthritis (pJIA) with polyarticular or oligoarticular onset. Patients received 8 mg/kg …

Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial

…, Y Ozeki, Y Kawano, Y Yamasaki, T Miyamae… - The Lancet, 2023 - thelancet.com
Background Juvenile idiopathic arthritis can be refractory to some or all treatment regimens,
therefore new medications are needed to treat this population. This trial assessed the …

Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case …

…, M Kikuchi, T Hara, T Nozawa, T Miyamae… - The Journal of …, 2012 - jrheum.org
Objective. Kawasaki disease (KD) is an acute febrile disease in infants and young children.
Five percent to 8% of cases will be complicated with coronary dilatation or aneurysm, …

Increased oxidative stress and coenzyme Q10 deficiency in juvenile fibromyalgia: amelioration of hypercholesterolemia and fatigue by ubiquinol-10 supplementation

T Miyamae, M Seki, T Naga, S Uchino, H Asazuma… - Redox …, 2013 - Taylor & Francis
Fibromyalgia (FM) is characterized by generalized pain and chronic fatigue of unknown
etiology. To evaluate the role of oxidative stress in this disorder, we measured plasma levels of …

Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan

S Yokota, T Imagawa, M Mori, T Miyamae… - The Journal of …, 2014 - jrheum.org
Miyamae is a joint patent holder for TCZ for treatment of sJIA. Dr. Umebayashi is on the
speakers’ bureaus for Chugai Pharmaceuticals and Pfizer and receives travel fees from Chugai …